Other · developed by Edesa Biotech
EB06 is an investigational agent given intravenously at a loading dose of 20 mg/kg followed by 10 mg/kg. It is being studied in non-segmental vitiligo.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07889492 | Phase 2 | Non-Segmental Vitiligo (NSV) | Recruiting | EDSA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Non-Segmental Vitiligo (NSV)
Updated Nov 15, 2026. Something wrong or missing? Report it on the EDSA page.
See EDSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EDSA catalysts and pipeline →